Alice Ramsey, MD
Family Medicine · Mineral Wells, TXNPI 1235137662
Payments from drug & device makers
Across 143 payments — averaging $17.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$469
- AbbVie$400
- AstraZeneca$398
- Lilly USA, LLC$308
- Pfizer$172
- Sumitomo Pharma America, Inc.$118
- plus $673 from 19 others
What the payments were for
- Food & beverage$2,51999%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 17 | $469 |
| AbbVie(2 entities) | 32 | $400 |
| AstraZeneca | 19 | $398 |
| Lilly USA, LLC | 19 | $308 |
| Pfizer | 13 | $172 |
| Sumitomo Pharma America, Inc. | 8 | $118 |
| Mylan Specialty L.p. | 5 | $92 |
| GE HealthCare | 1 | $72 |
| Boehringer Ingelheim | 4 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $55 |
| Astellas Pharma US Inc | 2 | $50 |
| Novo Nordisk | 3 | $42 |
| IBSA Pharma Inc. | 2 | $38 |
| Merck | 3 | $37 |
| GSK | 2 | $36 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Phathom Pharmaceuticals, Inc. | 1 | $27 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Bayer | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Abbott | 1 | $12 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$128
How this compares
$2,539 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 223 | $161,888 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 249 | $73,937 |
| JardianceEmpagliflozin | 90 | $68,994 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 91 | $66,475 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 279 | $58,292 |
| OzempicSemaglutide | 40 | $45,651 |
| XareltoRivaroxaban | 53 | $40,982 |
| FarxigaDapagliflozin Propanediol | 56 | $40,894 |
| MyrbetriqMirabegron | 76 | $37,894 |
| MounjaroTirzepatide | 32 | $34,043 |
| RybelsusSemaglutide | 20 | $26,269 |
| RexultiBrexpiprazole | 16 | $21,181 |
| TradjentaLinagliptin | 28 | $19,921 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 60 | $18,348 |
| GlyxambiEmpagliflozin/Linagliptin | 29 | $18,014 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKArexvy, Trelegy Ellipta, Shingrix, Anoro Ellipta | $36 | $204,210632 claims |
| PfizerEliquis, Abrysvo | $172 | $180,236283 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $69 | $106,929147 claims |
| Novo NordiskOzempic, Rybelsus | $42 | $71,92060 claims |
| Johnson & JohnsonXarelto | $12 | $40,98253 claims |
| AstraZenecaFarxiga | $398 | $40,89456 claims |
| Astellas Pharma US IncMyrbetriq | $50 | $37,89476 claims |
| Lilly USA, LLCMounjaro | $308 | $34,04332 claims |
| MerckJanuvia | $37 | $15,14636 claims |
| AbbVieLinzess, Synthroid | $400 | $10,14693 claims |
| Sanofi-aventis U.S. LLCMultaq | $23 | $8,77212 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $118 | $5,39412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Mineral Wells
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.